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Abstract
Background—Early antiretroviral therapy (ART) initiation in HIV-infected infants significantly 
improves survival but is often delayed in resource-limited settings. Adding HIV testing of infants 
at birth to the current recommendation of testing at age 4–6 weeks may improve testing rates and 
decrease time to ART initiation. We modeled the benefit of adding HIV testing at birth to the 
current 6-week testing algorithm.
Methods—Microsoft Excel was used to create a decision-tree model of the care continuum for 
the estimated 1,400,000 HIV-infected women and their infants in sub-Saharan Africa in 2012. The 
model assumed average published rates for facility births (42.9%), prevention of mother-to-child 
HIV transmission utilization (63%), mother-to-child-transmission rates based on prevention of 
mother-to-child HIV transmission regimen (5%–40%), return of test results (41%), enrollment in 
HIV care (52%), and ART initiation (54%). We conducted sensitivity analyses to model the impact 
of key variables and applied the model to specific country examples.
Results—Adding HIV testing at birth would increase the number of infants on ART by 204% by 
age 18 months. The greatest increase is seen in early ART initiations (543% by age 3 months). The 
increase would lead to a corresponding increase in survival at 12 months of age, with 5108 fewer 
infant deaths (44,550, versus 49,658).
Conclusion—Adding HIV testing at birth has the potential to improve the number and timing of 
ART initiation of HIV-infected infants, leading to a decrease in infant mortality. Using this model, 
countries should investigate a combination of HIV testing at birth and during the early infant 
period.
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In 2012, an estimated 260,000 children were newly infected with HIV worldwide1; 
approximately 90% of these infections occurred in sub-Saharan Africa through mother-to-
child transmission (MTCT).2 Without antiretroviral therapy (ART), 52% of HIV-infected 
infants die within 12 months after birth,3 with peak mortality occurring at 3 months of age.4 
Fortunately, survival rates improve greatly with ART, and studies have shown that infants 
initiated on ART before 12 weeks of age have up to a 76% reduction in mortality compared 
with infants in whom ART was delayed until a threshold CD4 percentage or presentation 
with a World Health Organization (WHO) clinical stage.5-7
Current WHO guidelines for resource-limited settings recommend virologic testing for HIV-
exposed infants at 4–6 weeks of age, but also allow for consideration of the addition of 
testing at birth.8 In resource-rich settings such as the United States, however, the standard 
practice is to provide virologic testing at multiple time points with the first as early as 14 
days or at birth for infants considered to be at high risk of HIV infection.9 There are 3 main 
rationales for WHO’s recommendation of 6-week testing in resource-limited settings: first, 
this timing coincides with the first scheduled infant vaccination visit at age 6 weeks; second, 
HIV DNA polymerase chain reaction (PCR) testing at 6 weeks is greater than 95% sensitive 
for all perinatal HIV transmissions (defined as in-utero or intrapartum transmission), which 
is higher than the sensitivity of HIV DNA PCR testing at birth10-12; and third, testing at age 
6 weeks can also detect a majority of early postnatal HIV transmissions (defined as 
transmission through breastfeeding).13 However, in practice, early infant diagnosis (EID) 
services are often not available, are poorly functioning, and have low follow-up rates; in 
2012, only 39% of HIV-exposed infants in resource-limited settings had an HIV DNA PCR 
test performed within 2 months of birth.1 Furthermore, even for those infants who receive 
testing, there are delays in treatment initiation once a positive result is returned to the health 
care provider. Recent studies have shown that average age of ART initiation among HIV-
infected infants diagnosed through EID services ranges widely, from 2 months to as long as 
11 months.14-18 Retaining HIV-exposed infants in care, returning HIV test results to their 
caregivers, and providing early ART to HIV-infected infants continue to be major challenges 
for prevention of mother-to-child HIV transmission (PMTCT) and pediatric HIV 
programs.19
One proposal for increasing early HIV testing and decreasing the time to infant ART 
initiation in resource-limited settings involves conducting the first HIV DNA PCR test 
shortly after birth.8,20 In this scenario, dried blood spot samples would be collected from all 
HIV-exposed infants born in health care facilities before discharge. HIV DNA PCR test 
results would be returned at the first scheduled postnatal vaccination visit at age 6 weeks. 
This approach offers several potential benefits. First, the number and proportion of HIV-
exposed infants in resource-limited settings who actually receive HIV testing could increase 
if HIV testing was included in the routine neonatal package of care currently offered after 
delivery. Second, for those who test positive, referral to HIV care services could be initiated 
at the time of the first immunization visit, which would potentially allow for treatment to be 
initiated at least 4 to 6 weeks earlier than with the current testing algorithm, even without 
improvements in specimen transport and laboratory processing turnaround time. Finally, 
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infants infected in-utero are known to have the most rapid progression of disease and would 
be the ones specifically identified through birth testing, permitting early life saving treatment 
for this highly vulnerable population.21 Despite these potential benefits, there are currently 
limited data on the impact of a newborn HIV testing program in resource-limited settings. To 
provide insight into this question, we modeled the use of HIV DNA PCR testing at birth to 
assess its impact on the number of HIV-infected infants initiated on treatment by ages 3 and 
18 months and the potential impact on HIV-related mortality.
METHODS
We used Microsoft Excel to create a decision-tree model of the continuum of care for HIV-
infected women and their infants in sub-Saharan Africa (Table 1). Our model included 
decision points for HIV-infected pregnant women during receipt of antenatal services 
through delivery and for their infants from birth through breastfeeding until 18 months of 
age. We searched PubMed and abstracts from relevant meetings [Conference on 
Retroviruses and Opportunistic Infections (CROI) and the International AIDS Society 
(IAS)] to identify rates from sub-Saharan Africa for each of the decision branch points along 
the cascade; we used a conservative median estimate for the model and conducted sensitivity 
analyses on assumptions used to gauge the effect of changing assumptions.
Assumptions for Pregnancy, Delivery, and Early MTCT
Our model was constructed using a theoretical cohort of 1,400,000 HIV-infected pregnant 
women, which is the number of HIV-infected pregnant women estimated to be living in sub-
Saharan Africa in 2012.1 Using published data for sub-Saharan Africa, we assumed that 
43% of births occurred in a health facility22; this was assumed to be the same for HIV-
infected and HIV-uninfected women. We modeled HIV transmission using varying rates of 
transmission depending on type of PMTCT regimen received. We estimated that 63% of all 
HIV-positive pregnant women would receive a highly effective PMTCT regimen (WHO 
Option A or B) and that the remaining women received no PMTCT interventions.1 The latest 
estimates of PMTCT utilization do not report single-dose nevirapine (sd-NVP) usage; 
however, as this regimen is still used in some settings in sub-Saharan Africa, we included it 
in the sensitivity analysis section of our model and used the most recently published estimate 
of sd-NVP use.33 Transmission rates for highly effective PMTCT, sd-NVP, and no PMTCT 
were estimated at 5.6%, 30.3%, and 40.3%, respectively, and incorporated the risk of 
postpartum transmission during 18 months of breastfeeding.33-35 We assumed that PMTCT 
intervention would affect the proportion of infant infections occurring perinatally; with 57% 
of HIV infections occurring perinatally as opposed to postpartum when a PMTCT 
intervention was provided compared with 70% when a woman received no PMTCT 
intervention.23,36 In total, this meant that 67.5% of HIV-positive infants in our model were 
infected perinatally.
Assumptions for HIV Testing of Exposed Infants at Birth
For our model of newborn HIV testing, we estimated that 80% of HIV-exposed infants born 
in facilities would have a dried blood spot sample for HIV DNA PCR test collected before 
discharge. This estimate was based on uptake of BCG vaccination, another service provided 
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at birth in resource-limited settings.37 Although uptake rates for HIV-related interventions 
may differ from uptake of other health interventions, multiple studies of HIV testing rates 
among pregnant women during delivery have shown that more than 85% of women accept 
testing for themselves38,39; acceptance rates for infant HIV testing offered to mothers in 
outpatient clinics are even higher.40
We assumed that HIV DNA PCR testing at birth would detect 60% of all infections acquired 
perinatally, but no postnatal infections. This sensitivity was based on data demonstrating that 
68% of perinatally infected infants identified by HIV DNA PCR testing at 6 weeks of age 
had also tested positive at birth, and other studies that tested infants at birth that showed 
lower sensitivities.12,25-27,41 Because we assumed that newborn test results would be 
returned at the first regularly scheduled vaccination visit at 6 weeks, we used vaccine uptake 
as a proxy of receipt of results. However, in our model, we used the 77% average rate of 
completion of the diphtheria-tetanus-pertussis (DTP) series at age 14 weeks rather than the 
85% rate of uptake of the first DTP vaccination to try to account for potential loss-to-follow-
up of infants whose mothers chose to receive vaccination services at sites different from 
delivery sites.37 One hindrance to receipt of results is long turnaround time of PCR testing, 
as samples are usually sent offsite to be performed. A review of studies showed that 
turnaround time can range from as little as 7 days to as long as 92 days.19,28,42-46 The 
weighted average of time was 28 days, and if using that assumption, all tests would be 
returned in time for the 6-week visit. However, pooling all studies, 20% of infants would not 
receive results by 6 weeks, and the model assumed that only 80% of results would be 
available at 6 weeks.
Assumptions for HIV Testing at 6 Weeks
We assumed that 39% of all HIV-exposed infants received HIV DNA PCR testing at 6 weeks 
and that this test had a sensitivity of 100% for perinatal HIV infections.1,47 We estimated 
that 63% of all postnatal transmissions would also be detected at age 6 weeks, based on data 
showing that HIV transmission is higher in the first 6 months of breastfeeding and gradually 
decreases over time.32
Assumptions for HIV Testing After 6 Weeks
We assumed that HIV-exposed breastfeeding infants who initially tested negative, regardless 
of the timing of the first test, had an additional HIV DNA PCR test schedule at 9 months, 
consistent with WHO recommendations.8 Our model assumed that 16% would not return for 
the 9-month test, consistent with the difference between 6-week DTP vaccination and 9-
month measles vaccination rates. We also assumed that 81% of postnatal infections in a 
breastfeeding infant would have occurred by that age and that all infections could be 
detected by a DNA PCR test.32 For the infants infected after 9 months of age, the final 
diagnostic test would be performed at 18 months, which was assumed to be the end of the 
breastfeeding period. Rates were assumed to be quite low, consistent with the 11% repeat 
measles vaccination, also given at 18 months. All infections of infants who would receive 
this test were considered to be detectable by rapid HIV antibody testing at this time point.
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Assumptions for Enrollment in HIV Care and Treatment
Based on current published data on linkage to care for HIV-infected infants in sub-Saharan 
Africa, we estimated that 52% of infants identified as HIV infected would enroll into 
care,16,19,28-31 and 54% of those enrolled into care would initiate ART.16,19,31 To determine 
the age at ART initiation, we assumed a median time of 10 weeks from the time of HIV 
diagnosis to the time of ART initiation.14,17,31 We used these same assumptions regardless 
of the testing algorithm or the infant’s age at HIV diagnosis.
Estimates of Infant Survival
To estimate the survival of HIV-infected infants, we assumed that HIV-infected women 
experienced rates of stillbirths of 2% for those not receiving any PMTCT and 4% for those 
receiving PMTCT.24 Among HIV-infected infants not receiving ART, we estimated a 12-
month mortality rate of 52% for perinatally infected infants and 26% for postnatally infected 
infants.3 Among HIV-infected infants receiving ART, we estimated 12-month mortality rates 
of 4% for those initiating ART before age 3 months and 16% for those initiating ART after 
age 3 months.3,5
Model Endpoints
Our model endpoints were the number of infants initiated on ART by ages 3 and 18 months 
and the number of HIV-related deaths prevented by 12 months. We compared these 
endpoints for infants who had a 6-week HIV DNA PCR test and for infants who had 
additional newborn DNA PCR testing.
Sensitivity Analysis and Country Examples
A 1-way sensitivity analysis was conducted for key variables in the model to determine their 
influence on the model endpoints. For this sensitivity analysis, we used the higher and lower 
published estimates of the following variables: facility births, PMTCT coverage, sd-NVP 
usage, newborn HIV testing rates, newborn HIV DNA PCR sensitivity, receipt of newborn 
test results, 6-week HIV testing rates, receipt of 6-week HIV test results, enrollment into 
care, and initiation of treatment (Table 2). We calculated outcomes using country-specific 
data for these key variables in 2 countries, Kenya and Swaziland, to illustrate the potential 
impact of newborn HIV testing in 2 sub-Saharan African settings with different HIV 
epidemics and health care systems (Table 3).
RESULTS
In our model, 600,600 (43%) of 1,400,000 HIV-infected women delivered in a health 
facility. Of these women, 378,378 (63%) received a WHO highly effective PMTCT regimen 
and 222,222 (37%) did not receive any PMTCT intervention. Among live births, 71,514 
(67%) infants were infected with HIV perinatally and an additional 34,377 (33%) were 
infected postnatally.
Compared with the standard 6-week HIV testing algorithm, the addition of DNA PCR 
testing at birth increased the number of infants initiated on ART at age 3 months by 543% 
(1907 with newborn and 6-week testing versus 351 with 6-week testing alone) and increased 
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the number of infected infants initiated on ART by age 18 months by 209% (9141 versus 
4372, respectively) (Fig. 1). The increase in the number of infants receiving early ART led to 
a corresponding increase in survival at 12 months of age, with 5108 fewer infant deaths 
(49,658 versus 44,550) as a result of earlier HIV diagnosis and ART initiation.
The sensitivity analysis showed that facility birth rates and enrollment in care are the 2 
decision-tree points that have the most effect on the impact of newborn HIV testing (Figs. 
2A–C). When facility birth rates reached 90%, as they are in the Republic of Congo,22 as 
opposed to the average of 43% across sub-Saharan Africa, the number of infants on ART by 
3 months using newborn HIV testing increased by 110% (2093 additional infants) and the 
number of deaths prevented increased by 110% (1877 additional lives saved) (Figs. 2A–C). 
The next largest influencer on the impact of newborn HIV testing was utilization of PMTCT. 
Here, the relationship was inverse, as the lower the usage of PMTCT, and correspondingly a 
larger number of peripartum transmissions, the larger the impact of newborn testing; if rates 
were as low as 6%, as they are in Nigeria (1), then the number of infants on ART by 3 
months increased by 109% (2071 additional infants), leading to a 107% increase in deaths 
prevented (1828 additional lives saved) (Figs. 2A–C).
Country Examples
Because of the wide variations in program performance across sub-Saharan Africa and the 
impact of various program factors on the outcome of the model, we sought to apply the 
model to specific country contexts. We used published data from Swaziland and Kenya to 
highlight the difference that key variables could have on the impact of newborn HIV testing. 
Compared with Kenya, Swaziland has a higher facility birth rate (74% versus 41%), higher 
HIV prevalence (31% versus 6.2%), and a higher current rate of 6-week HIV testing (81% 
versus 39%). Swaziland also has a much higher PMTCT utilization rate (83% versus 53%) 
(Table 3). Using these country-specific assumptions, our model showed that newborn HIV 
testing would have a larger impact in Kenya, increasing the number of infants on ART at age 
3 months by 359% compared with 249% in Swaziland (Table 4). This translates into 66 
more infant deaths prevented each year in Kenya using newborn testing compared with 9 
infant deaths per year prevented using newborn testing in Swaziland (Table 4).
DISCUSSION
Our model shows that newborn HIV DNA PCR testing in sub-Saharan Africa has the 
potential to increase the number of infected infants initiated on treatment before the age of 3 
months and significantly reduce infant mortality due to perinatally acquired HIV; the 
addition of newborn HIV testing would increase the number of infants on ART by 3 months 
by 543% and help prevent 5108 HIV-related infant deaths at 12 months of age. Although this 
model provides insight into the potential impact of newborn testing in sub-Saharan Africa, 
the real impact of newborn testing will be highly variable based on a country’s specific 
burden of HIV and program performance. Our sensitivity analysis showed that newborn 
testing would have the largest impact and prevent the most deaths in countries with a high 
proportion of facility births and the countries with the lowest PMTCT rates. In our country 
examples, although Swaziland has stronger systems once infected children are identified, the 
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fact that Kenya has lower PMTCT rates, translating into more peripartum infections, 
increases the potential of newborn testing to find more HIV-infected infants in that country.
Our model has several limitations. First, our model assumptions were based on published 
data on the cascade of care for HIV-infected women and their infants across sub-Saharan 
Africa. The published rates may not reflect the most recent performance and may present a 
biased picture of program performance by ignoring improvements in care delivery that have 
been made in recent years. Although we used the most recent data available at the time of 
our analysis, new data have likely become available in the interim that could change the 
modeled impact of birth testing. Second, our model assumptions about uptake of newborn 
HIV testing and return of test results were based on data from usage of other services, 
including vaccination services. One of the largest programmatic hurdles for a successful 
newborn HIV testing program would be the return of results at the 6-week immunization 
visit, especially as immunization services are often more decentralized than maternity 
facilities and that women may choose not to return to the same clinic where they delivered 
for their infant’s immunizations. A study to better estimate these rates and understand the 
programmatic feasibility, including costs, of newborn testing is needed. Third, many of our 
assumptions are derived from studies that did not focus on HIV-infected women who deliver 
in health care facilities. The women who choose to deliver in a health care facility may not 
be representative of the larger population of HIV-infected women, as they may have greater 
access to health care and may be more likely to use PMTCT and HIV-exposed infant follow-
up services including EID. In our model, we assumed that HIV-infected and HIV-uninfected 
women would deliver in health facilities at the same rates; however, as HIV is often more 
common in urban areas, where the density of health facilities is higher and where women 
have higher uptake of facility births, HIV-infected women may be more likely to deliver in 
health care facilities, thus underestimating the effect of newborn testing. Our model could 
not account for these issues, mainly because this type of stratified data is not available. 
Finally, newborn testing would not replace the need for an additional HIV DNA PCR test at 
a later age, as false negatives could occur, a number of intrapartum infections would be 
missed, and early breastfeeding transmissions would not be detected. Therefore, if a country 
implemented a newborn HIV testing model, infants testing negative at birth would require at 
least 2 HIV DNA PCR tests, meaning that additional commodities and laboratory capacity 
would be required. A formal costing analysis of newborn HIV testing is needed to inform 
international and country-specific decisions regarding the feasibility of implementing a 
newborn HIV testing program.
Newborn testing should continue to be evaluated as a potential addition to other strategies 
for earlier HIV diagnosis and treatment initiation in infants. Pilot studies and operational 
research are urgently needed to better determine the true impact that this strategy could have, 
and how postnatal transmission changes might influence the timing of subsequent testing, 
especially in settings where PMTCT services, including universal ART for life for HIV-
infected pregnant and breastfeeding women, are rapidly expanding.49 Small-scale trials of 
newborn HIV testing in delivery wards could help verify key model assumptions, such as 
acceptance of newborn HIV testing and receipt of HIV test results at the 6-week vaccination 
visit. These pilot projects would also help identify unforeseen logistical obstacles to 
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newborn testing and assess the feasibility of coordination between HIV testing in the 
delivery ward and return of results at an immunization clinic.
In addition to pilot testing, additional modeling should be performed to account for the 
introduction of new technologies, such as ultrasensitive and point-of-care HIV DNA PCR 
tests or PMTCT program improvements. In addition, new algorithms for infant HIV testing 
should be explored, particularly combinations of newborn testing with a second HIV test 
that could be performed at a time later than the 6-week visit to capture more postnatal 
transmissions; 10 weeks has been suggested.50 Further modeling is needed to identify an 
optimal testing algorithm that maximizes both timely HIV diagnosis and infant lives saved 
and that minimizes cost. Finally, as we have shown, the impact of newborn testing is highly 
context dependent, meaning that countries and even individual health centers need to 
consider their individual program context as they evaluate the utility of newborn HIV 
testing.
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Model estimates of the number of children initiated on ART by 3 and 18 months with 
current testing practices and with the addition of newborn testing.
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A, Sensitivity analysis of the impact of newborn testing in settings with high and low 
estimates of key variables in the model compared with average estimates in percent change 
of infants on ART by age 3 months. B, Sensitivity analysis of the impact of newborn testing 
in settings with high and low estimates of key variables in the model compared with average 
estimates in percent change of infants on ART by 18 months. C, Sensitivity analysis of the 
impact of newborn testing in settings with high and low estimates of key variables in the 
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model compared with average estimates in percent change in number of additional infant 
deaths prevented at age 12 months.
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TABLE 1
Assumption Values, Including High and Low Estimates of Each Model Parameter Used in Sensitivity 
Analysis, and Source
Parameter Average Value, % Range Source
Facility births 42.9 14%–90% Montagu et al22
PMTCT utilization UNAIDS Global Report 2013
 Highly effective regimen 63 7%–95%
 None 37
HIV transmission rates Working Paper on Mother-to- Child HIV Transmission Rates 
for use in Spectrum 2011
 Highly effective regimen 5.6
 Slightly effective regimen 30.3
 None 40.3
Timing of transmission without PMTCT* Cavarelli et al23
 Peripartum (in-utero and intrapartum) 70
 Postpartum 30
Timing of transmission with PMTCT Kesho Bora Study Group 2011
 Peripartum (in-utero and intrapartum) 57
 Postpartum 43
At birth survival Chen et al24
 Baseline for HIV+ infants 96
 On PMTCT therapy 94
HIV testing rate WHO Vaccine Preventable Disease Monitoring System 2012; 
UNAIDS Global Report 2013
 Newborn testing 80 78%–86%
 6-wk testing 39 3%–95%
HIV DNA PCR test sensitivity Lilian et al12; Neilsen-Saines et al25; Burgard et al26; and 
Shapiro et al27
 Newborn testing 60 50%–70%
 6-wk testing 100
Return of test eesults WHO Vaccine Preventable Disease Monitoring System 2012; 
estimated range of ±15%; Ciaranello et al19; Anoje et al28; 
Coulibaly et al16; Hsiao et al29; Hassan et al30; and Motswere- 
Chirwa et al31
Newborn testing 71 56%–86%
6-wk testing 52 45%–99%
Enrollment into care 52 30%–78% Ciaranello et al19; Coulibaly et al16; and Motswere-Chirwa et 
al31
Initiation of ART 54 38%–77% Ciaranello et al19; Braun et al14; Motswere-Chirwa et al31; and 
Innes et al17
Treatment within 3 mo of life Braun et al14;Motswere-Chirwa et al31; and Innes et al17
 Newborn testing 37.5
 6-wk testing 8
Treatment within 6 mo of life Braun et al14; Motswere-Chirwa31; and Innes et al17
 Newborn testing 59
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Parameter Average Value, % Range Source
 6-wk testing 54
Treatment within 12 mo of life Braun et al14; Motswere-Chirwa et al31; and Innes et al17
 Newborn testing 80
 6-wk testing 75
Postpartum transmission timing Nduati et al32
 within 6 wk 63
 within 9 mo 81
 within 18 mo 100
1 yr mortality Marston et al51; and Violari et al5
 Peripartum no treatment 48
 Postpartum no treatment 24
 On delayed treatment 16
 On treatment by 3 mo 4
*
PMTCT defined as WHO Option A or B.
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TABLE 3
Key Variables for Models of the Impact of Newborn HIV Testing in Kenya and Swaziland
Variable Kenya Swaziland
Number of HIV-infected pregnant women1 86,000 12,000
% of births occurring at health care facilities22 41 74
Uptake of highly effective PMTCT* regimen among pregnant women,1 % 53 83
% of HIV-exposed infants receiving HIV DNA PCR testing at 2 mo1 39 81
% of infants whose mothers receive 6-wk HIV DNA PCR test results48 71 50
% of HIV-infected infants enrolled into HIV care48 42 75
% of HIV-infected infants who initiate ART1,48 49 59
*
PMTCT.
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TABLE 4
Infant ART Initiation at 3 and 18 Months, and Lives Saved by Adding Newborn Testing to Routine Infant HIV 
Testing Algorithms in Kenya and Swaziland
Increase in Infants on Treatment by 3 mo Increase in Infants on Treatment by 18 mo Additional Lives Saved per Year
Kenya 78 (359%) 178 (147%) 66
Swaziland 18 (249%) 22 (113%) 9
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